His primary areas of investigation include Internal medicine, Renal cell carcinoma, Oncology, Melanoma and Immunology. His studies deal with areas such as Gastroenterology and Surgery as well as Internal medicine. Michael B. Atkins combines subjects such as Odds ratio, Kidney disease, Temsirolimus, Carcinoma and Antibody with his study of Renal cell carcinoma.
His study in Oncology is interdisciplinary in nature, drawing from both Avelumab, Colorectal cancer, Tolerability and Survival analysis. His work in Melanoma tackles topics such as Ipilimumab which are related to areas like Dabrafenib, Vemurafenib and Trametinib. His research in Immunology intersects with topics in Cancer and Cancer research.
Michael B. Atkins focuses on Internal medicine, Oncology, Renal cell carcinoma, Melanoma and Cancer. His Internal medicine research incorporates themes from Gastroenterology and Surgery. His Surgery research is multidisciplinary, incorporating elements of Alpha interferon and Toxicity.
His Oncology research also works with subjects such as
Michael B. Atkins mostly deals with Internal medicine, Oncology, Renal cell carcinoma, In patient and Pembrolizumab. His Internal medicine study often links to related topics such as Melanoma. His work deals with themes such as Targeted therapy, Disease and Adjuvant therapy, which intersect with Melanoma.
His Oncology study combines topics in areas such as Checkmate, Advanced melanoma, Immunotherapy and Phases of clinical research. His biological study spans a wide range of topics, including Sorafenib and Hazard ratio. His research on Pembrolizumab concerns the broader Cancer.
His primary scientific interests are in Internal medicine, Oncology, Renal cell carcinoma, Nivolumab and Pembrolizumab. His Clinical trial, Cohort, Survival rate, Targeted therapy and Adjuvant therapy study are his primary interests in Internal medicine. Michael B. Atkins has researched Oncology in several fields, including Randomized controlled trial, Phases of clinical research and Carcinoma.
His Renal cell carcinoma research integrates issues from Sickle cell trait, Renal medullary carcinoma and Nephrectomy. The study incorporates disciplines such as Ipilimumab and Melanoma in addition to Nivolumab. Michael B. Atkins works mostly in the field of Pembrolizumab, limiting it down to topics relating to Axitinib and, in certain cases, Progression-free survival, First line therapy and Avelumab, as a part of the same area of interest.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger.
The New England Journal of Medicine (2012)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch;Jeffrey E. Gershenwald;Seng Jaw Soong;John F. Thompson.
Journal of Clinical Oncology (2009)
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton;Margaret Morgan;Preethi H. Gunaratne;Preethi H. Gunaratne;David A. Wheeler.
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
Charles M. Balch;Antonio C. Buzaid;Seng-Jaw Soong;Michael B. Atkins.
Journal of Clinical Oncology (2001)
Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
Charles M. Balch;Seng-Jaw Soong;Jeffrey E. Gershenwald;John F. Thompson.
Journal of Clinical Oncology (2001)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins.
Journal of Clinical Oncology (2018)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger.
Journal of Clinical Oncology (2014)
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
Michael B. Atkins;Michael T. Lotze;Janice P. Dutcher;Richard I. Fisher.
Journal of Clinical Oncology (1999)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini;Elizabeth R. Plimack;Viktor Stus;Rustem Gafanov.
The New England Journal of Medicine (2019)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas.
The New England Journal of Medicine (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: